Regulatory Approvals

FDA Approves LYTENAVA, First Ophthalmic Bevacizumab for Wet AMD

By

Regulatory Approvals — FDA Approves LYTENAVA, First Ophthalmic Bevacizumab for Wet AMD  The Clinical Trial Vanguard

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. July 25, 2026.

By

Related Post

Regulatory Approvals

FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults

Regulatory Approvals

FDA Clears Roche cobas BV/CV PCR Assay for Simultaneous Vaginitis Detection

Regulatory Approvals

FDA approves Outlook Therapeutics’ LYTENAVA for the treatment of wet AMD

Financial News For All

Business Economy Finance

Commodities Price Update: Crude Oil $89.31, Brent $96.78, Copper $6.36, Coal $104.75 — Jul 25, 2026 8:00 AM EDT

Litigation

Here’s how to claim your refund from $2.5 billion FTC deal in Amazon Prime settlement

Litigation

ACLU of Colorado Statement on DOJ Lawsuit Challenging Colorado Law Granting In-State Tuition to Immigrant Students

Mergers & Acquisitions

Here’s Why Paramount’s Decision To Delay WBD Merger Could Cost It Over $1 Billion